Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

MIAMI, FL — The FGC2.3: Feline Vocalization Classification and Cat Translation Project, authored by Dr. Vladislav Reznikov, has crossed a critical scientific milestone — surpassing 14,000 reads on ResearchGate and rapidly climbing toward record-setting levels in the field of animal communication and artificial intelligence. This pioneering work aims to develop the world’s first scientifically grounded…

Tariff-Free Relocation to the US

Tariff-Free Relocation to the US

EU, China, and more are now in the crosshairs. How’s next? It’s time to act. The Trump administration has announced sweeping tariff hikes, as high as 50%, on imports from the European Union, China, and other major markets. Affected industries? Pharmaceuticals, Biotech, Medical Devices, IVD, and Food Supplements — core sectors now facing crippling costs,…

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

This study presents the GDP Matrix by Dr. Vlad Reznikov, a bubble chart designed to clarify the complex relationships between GDP, PPP, and population data by categorizing countries into four quadrants—ROCKSTARS, HONEYBEES, MAVERICKS, and UNDERDOGS depending on National Regulatory Authorities (NRAs) Maturity Level (ML) of the regulatory affairs requirements for healthcare products. Find more details…

EMA Suggests Broadened Use of Mpox Vaccine to Include Adolescent Population

EMA Suggests Broadened Use of Mpox Vaccine to Include Adolescent Population

The European Commission has issued its decision on the Imvanex extension of indication in adolescents on 19 September 2024., EMA has recommended extending the indication of the smallpox and mpox vaccine Imvanex to adolescents from 12 to 17 years of age.Imvanex is already authorised in the European Union…

New Chair Elected to EMA’s Committee for Human Medicines

New Chair Elected to EMA’s Committee for Human Medicines

At its September 2024 meeting, EMA’s Committee for Human Medicinal Products (CHMP) elected Bruno Sepodes as its new chair. Professor Sepodes starts his three-year mandate on 21…, “As chair of the CHMP, my number one priority is ensuring the highest standards of medicine quality, safety and efficacy for patients in the European Union (EU).
Together, we…, Prof. Bruno Sepodes succeeds Dr Harald Enzmann as chair, who completed the maximum two three-year terms allowed for CHMP chairs.CHMP is the committee at EMA responsible for…

Elon Musk’s New Device, Enabling Blind People To See, Put on Fast Track by FDA

Elon Musk’s New Device, Enabling Blind People To See, Put on Fast Track by FDA

Neuralink’s groundbreaking Blindsight device, designed to restore vision for the blind, has been granted Breakthrough Device Designation by the FDA. This innovative technology has the potential to help individuals who have lost both eyes and their optic nerve regain sight, as long as their visual cortex remains functional. Remarkably, it could even allow people born…

EMA’s Orphan Medicinal Products Committee Welcomes Newly Elected Chair

EMA’s Orphan Medicinal Products Committee Welcomes Newly Elected Chair

EMA’s Committee for Orphan Medicinal Products (COMP) elected a new chair. Tim Leest starts his three-year mandate today, 16 September.A Belgian national, Tim Leest holds a master’…, “We have a duty towards patients who go through life with the burden of an orphan disease.
I am fully committed to continuing our committee’s excellent work and fostering…, Tim Leest succeeds Dr Violeta Stoyanova-Beninska as a chair, following her completion of the maximum two three-year terms allowed for COMP chairs.COMP is responsible for…

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 September 2024

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 September 2024

EMA recommends measures to minimise serious outcomes of known side effect with painkiller metamizoleProduct information to be updated to raise awareness of known risk of…, Agenda Agenda of the PRAC meeting 2-5 September 2024DraftReference Number: EMA/PRAC/323875/2024 English (EN…, PRAC statistics: September 2024 , PRAC statistics: September 2024 English (EN) (33.15 MB – PDF)First published: 06/09/2024View, Glossary Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association…, Ongoing referrals ProcedureStatusUpdateMetamizole containing medicinal products – referralUnder evaluationPRAC continued its assessment